Trastuzumab for the treatment of primary breast cancer in HER2-positive women: A single technology appraisal

Health Technology Assessment

Volumn 13, Issue SUPPL.1, 2009, Pages 1-6

  Ward, Sue ^a   Pilgrim, H ^a   Hind, D ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; METABOLISM; PHASE 3 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; RECEPTOR, ERBB-2; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 70349241801     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl1/01     Document Type: Article

References (8)

1. National Institute for Health and Clinical Excellence. Guide to the single technology (STA) process. 19 September 2006. URL: www.nice.org.uk/page.aspx?o=STAprocessguide
2. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Evidence review group single technology appraisal for NICE. May 2006.
3. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. FinHer Study I, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
4. Piccant-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsh A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005;353:1657-72.
5. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis. The 28th Annual San Antonio Cancer Symposium, 8-11 December 2005, San Antonio, TX, USA.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
7. Karnon J, Delea T, Johnston S, Smith R, Brandman J. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy. Pharmacoeconomics 2006;24:237-50.
8. Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004;91:77-83.